Patents by Inventor Frank Rigo

Frank Rigo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT
    Publication number: 20180142240
    Abstract: Disclosed herein are compositions and methods for reducing expression of C9ORF72 antisense transcript in an animal with C9ORF72 antisense transcript specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C9ORF72 antisense transcript specific inhibitors include antisense compounds.
    Type: Application
    Filed: December 20, 2017
    Publication date: May 24, 2018
    Applicants: Ionis Pharmaceuticals, Inc., The Regents of the University of California, Ludwig Institute for Cancer Research
    Inventors: C. Frank Bennett, Frank Rigo, Don W. Cleveland, Clotilde Lagier-Tourenne, John M. Ravits, Michael W. Baughn
  • ANTISENSE COMPOUNDS TARGETING GENES ASSOCIATED WITH FIBRONECTIN
    Publication number: 20180127751
    Abstract: The present invention provides compounds comprising oligonucleotides complementary to a fibronectin transcript. Certain such compounds are useful for hybridizing to a fibronectin transcript, including but not limited to a fibronectin transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the fibronectin transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with fibrosis. In certain embodiments, such compounds are used to treat one or more symptoms associated with renal fibrosis.
    Type: Application
    Filed: October 27, 2017
    Publication date: May 10, 2018
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Frank Rigo
  • Methods for modulating C9ORF72 expression
    Patent number: 9963699
    Abstract: Disclosed herein are methods for reducing expression of C90RF72 mRNA and protein in an animal with C90RF72 specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C90RF72 specific inhibitors include antisense compounds. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration C90RF72 specific inhibitors include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), corticalbasal degeneration syndrome (CBD), atypical Parkinsonian syndrome, and olivopontocerellar degeneration (OPCD).
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: May 8, 2018
    Assignees: Ionis Pharmaceuticals, Inc., Ludwig Institute for Cancer Research, The Regents of the University of California
    Inventors: C. Frank Bennett, Susan M. Freier, Frank Rigo, Don W. Cleveland, Clotilde Lagier-Tourenne, John M. Ravits, Michael W. Baughn
  • COMPOSITIONS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT
    Publication number: 20180119142
    Abstract: Disclosed herein are compositions and methods for modulating expression of C9ORF72 antisense transcript in a cell or animal with C9ORF72 antisense transcript specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C9ORF72 antisense transcript specific inhibitors include antisense compounds.
    Type: Application
    Filed: April 16, 2015
    Publication date: May 3, 2018
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventor: Frank Rigo
  • Compositions and methods for modulation of SMN2 splicing in a subject
    Patent number: 9926559
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: March 27, 2018
    Assignee: Biogen MA Inc.
    Inventors: C. Frank Bennett, Gene Hung, Frank Rigo
  • COMPOSITIONS AND METHODS FOR MODULATING TAU EXPRESSION
    Publication number: 20180051283
    Abstract: Disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Also disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Such compounds and methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.
    Type: Application
    Filed: March 28, 2017
    Publication date: February 22, 2018
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventor: Frank Rigo
  • COMPOSITIONS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT
    Publication number: 20180023077
    Abstract: Disclosed herein are compositions and methods for reducing expression of C9ORF72 antisense transcript in an animal with C9ORF72 antisense transcript specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C9ORF72 antisense transcript specific inhibitors include antisense compounds.
    Type: Application
    Filed: January 6, 2016
    Publication date: January 25, 2018
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventor: Frank Rigo
  • MODULATION OF UBE3A-ATS EXPRESSION
    Publication number: 20170362592
    Abstract: Certain embodiments are directed to methods and compounds for inhibiting UBE3A-ATS, the endogenous antisense transcript of ubiquitin protein ligase E3A (UBE3A). Such methods and compounds are useful for. Several embodiments provided herein relate to the discovery that antisense compounds targeting UBE3A-ATS induce paternal expression of UBE3A. Several embodiments are drawn to methods and compounds for inducing paternal expression of UBE3A using antisense compounds targeting UBE3A-ATS within a region of UBE3A-ATS that includes the sequence of the small nucleolar RNA (snoRNA), HBII-85 (also referred to as SNORD116).
    Type: Application
    Filed: November 25, 2015
    Publication date: December 21, 2017
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Amanda Ward, Frank Rigo
  • COMPOSITIONS AND METHODS FOR DETECTION OF SMN PROTEIN IN A SUBJECT AND TREATMENT OF A SUBJECT
    Publication number: 20170363643
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy. Also provided are kits for detecting the amount of SMN protein in a sample of cerebrospinal fluid.
    Type: Application
    Filed: September 11, 2015
    Publication date: December 21, 2017
    Inventors: Frank Rigo, Katherine M. Bishop
  • COMPOSITIONS FOR MODULATING C9ORF72 EXPRESSION
    Publication number: 20170349897
    Abstract: Disclosed herein are compositions and methods for reducing expression of C9ORF72 mRNA and protein in an animal. Such methods are useful to treat, prevent, ameliorate, or slow progression of neurodegenerative diseases in an individual in need thereof.
    Type: Application
    Filed: January 12, 2017
    Publication date: December 7, 2017
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventor: Frank Rigo
  • Antisense compounds targeting genes associated with fibronectin
    Patent number: 9828602
    Abstract: The present invention provides compounds comprising oligonucleotides complementary to a fibronectin transcript. Certain such compounds are useful for hybridizing to a fibronectin transcript, including but not limited to a fibronectin transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the fibronectin transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with fibrosis. In certain embodiments, such compounds are used to treat one or more symptoms associated with renal fibrosis.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: November 28, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Frank Rigo
  • ANTISENSE COMPOUNDS AND USES THEREOF
    Publication number: 20170268000
    Abstract: The present invention provides compounds comprising oligonucleotides complementary to a CLN3 transcript. Certain such compounds are useful for hybridizing to a CLN3 transcript, including but not limited to a CLN3 transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CLN3 transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Batten Disease.
    Type: Application
    Filed: December 2, 2014
    Publication date: September 21, 2017
    Applicants: Ionis Pharmaceuticals, Inc., Rosalind Franklin University of Medicine and Science
    Inventors: Frank RIGO, Michelle L. HASTINGS
  • Compositions and methods for modulation of SMN2 splicing in a subject
    Patent number: 9717750
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: August 1, 2017
    Assignees: Biogen MA Inc., Cold Spring Harbor Laboratory
    Inventors: C. Frank Bennett, Gene Hung, Frank Rigo, Adrian R. Krainer, Yimin Hua, Marco A. Passini, Lamya Shihabuddin, Seng H. Cheng, Katherine W. Klinger
  • COMPOSITIONS AND METHODS FOR MODULATING TAU EXPRESSION
    Publication number: 20170211064
    Abstract: Disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Also disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.
    Type: Application
    Filed: July 29, 2015
    Publication date: July 27, 2017
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventor: Frank Rigo
  • ANTISENSE COMPOUNDS TARGETING APOLIPOPROTEIN E RECEPTOR 2
    Publication number: 20170191066
    Abstract: The present invention provides compounds comprising oligonucleotides complementary to an LRP8 transcript. Certain such compounds are useful for hybridizing to an LRP8 transcript, including but not limited, to an LRP8 transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRP8 transcript. In certain embodiments, such hybridization results in an increase in inclusion of exon 19 in the LRP8 mRNA transcript. In certain embodiments, such compounds are used to treat Alzheimer's Disease.
    Type: Application
    Filed: June 4, 2015
    Publication date: July 6, 2017
    Applicants: Ionis Pharmaceuticals, Inc., Rosalind Franklin University of Medicine and Science
    Inventors: Frank Rigo, Michelle L. Hastings
  • Compositions and methods for modulating Tau expression
    Patent number: 9644207
    Abstract: Disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Also disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Such compounds and methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 9, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Frank Rigo, Susan M. Freier
  • Modulation of UBE3A-ATS expression
    Patent number: 9617539
    Abstract: Certain embodiments are directed to methods and compounds for inhibiting UBE3A-ATS, the endogenous antisense transcript of ubiquitin protein ligase E3A (UBE3A). Such methods and compounds are useful for inducing expression of paternal UBE3A in cells and animals.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: April 11, 2017
    Assignees: Ionis Pharmaceuticals, Inc., Baylor College of Medicine
    Inventors: Frank Rigo, Amanda Ward, Linyan Meng, Arthur L. Beaudet
  • Compositions for modulating C9ORF72 expression
    Patent number: 9605263
    Abstract: Disclosed herein are compositions and methods for reducing expression of C9ORF72 mRNA and protein in an animal. Such methods are useful to treat, prevent, ameliorate, or slow progression of neurodegenerative diseases in an individual in need thereof.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: March 28, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventor: Frank Rigo
  • Compositions and Methods for Modulation of SMN2 Splicing in a Subject
    Publication number: 20170044538
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject.
    Type: Application
    Filed: April 17, 2015
    Publication date: February 16, 2017
    Inventors: Frank RIGO, C. Frank BENNETT
  • COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING IN A SUBJECT
    Publication number: 20170015995
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.
    Type: Application
    Filed: February 9, 2015
    Publication date: January 19, 2017
    Applicants: Ionis Pharmaceuticals, Inc., Cold Spring Harbor Laboratory
    Inventors: C. Frank Bennett, Gene Hung, Frank Rigo, Adrian R. Krainer, Yimin Hua, Marco A. Passini, Lamya Shihabuddin, Seng H. Cheng, Katherine W. Klinger